Ito, F., & Furukawa, N. (2017). Effectiveness of antiemetic triplet therapy with aprepitant, palonosetron, and dexamethasone for gynecologic cancer patients receiving carboplatin and paclitaxel: A prospective single-arm study. Supportive Care in Cancer, 25, 1941–1945.
The purpose of this study was to evaluate the efficacy of triplet therapy aprepitant, palonosetron, and dexamethasone in patients receiving carboplatin and paclitaxel (CP) for gynecologic malignancy.
Seventy patients with gynecologic cancer receiving CP were enrolled into a prospective single-arm study with APR (125 mg on day 1, 80 mg on days 2–3), PALO (0.75 mg), and DEX (20 mg) before initiating chemotherapy. The primary endpoint was delayed complete response (CR) rate (i.e., no vomiting and no rescue) at 24–120 hours after chemotherapy administration.
Single-arm phase II
Adding APR to PALO and DEX combination therapy may be promising for patients with gynecologic cancer receiving CP. A phase III study comparing APR, PALO, and DEX to PALO and DEX should be conducted in order to determine if APR in addition to PALO and DEX is efficacious for female patients receiving CP.
Encourage more studies to better determine the efficiency of APR in addition to PALO and DEX in this patient population.